Loading…
Lobbying Spend
—
Filings
726
Firms Hired
13
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · third_quarter · Firm: FARRAGUT PARTNERS LLP
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Tax Exempt Hospital Transparency Act
2026 · third_quarter · Firm: THE MCMANUS GROUP
Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 9504
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to the SECURE 340B Act (H.R.9599).
Client expense: — · Firm income: $50,000
Matched citations: H.R.9599
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Tax Exempt Hospital Transparency Act
2026 · second_quarter · Firm: THE MCMANUS GROUP
Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 9504
Protecting Patient Access to Cancer and Complex Therapies Act
2026 · second_quarter · Firm: FARRAGUT PARTNERS LLP
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Methane Waste Prevention Act of 2021
2026 · first_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Methane Waste Prevention Act of 2021
2025 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Methane Waste Prevention Act of 2021
2025 · third_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 4299
Methane Waste Prevention Act of 2021
2025 · second_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1492
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 1672- Maintaining Investments in New Innovation Act. Issues related to physician reimbursement for Part B drugs.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1672
To amend the Occupational Safety and Health Act of 1970 to prohibit emergency temporary standards with respect to vaccines, and for other purposes.
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476 - Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.5391
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476 - Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.5547
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.10445
American Innovation and R&D Competitiveness Act of 2023
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023 H.R.7024 - Tax Relief for American Families and Workers Act of 2024 S.866 - American Innovation and Jobs Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2673
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3290
Tax Relief for American Families and Workers Act of 2024
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023 H.R.7024 - Tax Relief for American Families and Workers Act of 2024 S.866 - American Innovation and Jobs Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.7024
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476 - Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: S. 2764
Pandemic Heroes Compensation Act of 2021
2024 · fourth_quarter · Firm: THE MCMANUS GROUP
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. S. 2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to PBM provisions included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5547/S. 476 - Maintaining Investments in New Innovation Act
Client expense: — · Firm income: $50,000
Matched citations: S. 476
Issues related to research and development tax amortization in H.R. 2673 American Innovation and R&D competitiveness Act of 2023 H.R.7024 - Tax Relief for American Families and Workers Act of 2024 S.866 - American Innovation and Jobs Act
Client expense: — · Firm income: $50,000
Matched citations: S.866
Inflation Reduction Act of 2022
2024 · fourth_quarter · Firm: CAPITOL COUNSEL LLC
Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements, including related provisions in H.R. 5376, the Inflation Reduction Act of 2022 (P.L. 117-169): Title 1, Subtitle B - Prescription Drug Pricing Reform: Part 1, Lowering Prices Through Drug Price Negotiation; Part 2, Prescription Drug Inflation Rebates; and Part 3, Part D Improvements and Maximum Out-of-Pocket Cap for Medicare Beneficiaries. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5376
Source: Senate LDA